JENNIFER DISMUKES: Open Payments
NPI 1396818076 · SKILLMAN, NJ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$12,771 in 64 payments from 10 companies in 2025. Trend: 2023 $274 · 2024 $1,044 · 2025 $12,771
Consulting: $10,015Food & beverage: $1,770Travel & lodging: $986
| Company | Payments | Amount |
|---|---|---|
| E.R. Squibb & Sons, L.L.C. | 14 | $11,470 |
| Otsuka America Pharmaceutical, Inc. | 7 | $385 |
| Axsome Therapeutics, Inc. | 2 | $243 |
| Teva Pharmaceuticals USA, Inc. | 17 | $218 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 9 | $205 |
| Alkermes, Inc. | 6 | $114 |
| Luye Pharma (USA) Ltd. | 5 | $72 |
| Lundbeck LLC | 2 | $32 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $18 |
| IDORSIA PHARMACEUTICALS US INC | 1 | $14 |
Products named: COBENFY, REXULTI, Auvelity, CAPLYTA, UZEDY, ARISTADA, ABILIFY ASIMTUFII, ERZOFRI EXTENDED-RELEASE.
Industry payments across NJ — which companies pay providers there.
